Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows - Telomir Pharmaceuticals ( NASDAQ:TELO )
Telomir-1 reduced tumor size by 50% in a prostate cancer model and protected against chemotherapy-induced toxicity. Telomir Pharmaceuticals plans to submit an IND application by year-end to advance Telomir-1 into clinical trials. Our government trade tracker caught Pelosi's 169% AI winner.
Cerro de Pasco Reports Final Quiulacocha Assays, Confirming High-Grade Silver, Zinc, Lead, Copper, Gold, and Gallium Intersections
The findings confirm the consistent presence of silver and gallium across the drilled area, with average grades exceeding 50 g/t for both metals.
Southern Michigan Bancorp, Inc. Announces Increase in Quarterly Dividend
COLDWATER, Mich., March 19, 2025 ( GLOBE NEWSWIRE ) -- The Board of Directors of Southern Michigan Bancorp, Inc. ( OTC Pink: SOMC ) approved an increase to the quarterly cash dividend that will be paid in April 2025. The $0.16 per share dividend is an increase of $0.01 per share over the January ...
Southern Michigan Bancorp, Inc. Announces Increase in Quarterly Dividend - Southern Michigan Bancorp ( OTC:SOMC )
COLDWATER, Mich., March 19, 2025 ( GLOBE NEWSWIRE ) -- The Board of Directors of Southern Michigan Bancorp, Inc. SOMC approved an increase to the quarterly cash dividend that will be paid in April 2025. The $0.16 per share dividend is an increase of $0.01 per share over the January 2025 cash ...
Frequency Electronics, Inc. Recognized by Northrop Grumman with Supplier Excellence Award
MITCHEL FIELD, N.Y., March 19, 2025 ( GLOBE NEWSWIRE ) -- Frequency Electronics, Inc. ( "FEI" or the "Company" ) ( NASDAQ-FEIM ) , a leading provider of precision timing and frequency control products, is pleased to announce that Northrop Grumman Corporation ( NYSE:NOC ) has recognized Frequency ...
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Studies
NEW YORK, March 19, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period ...
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Studies
NEW YORK, March 19, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period ...
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Studies - Immunovant ( NASDAQ:IMVT )
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm ( with 74% mean IgG reduction ) and a 4.7 point improvement in the lower dose arm ( with 64% mean IgG reduction )
Recession Would Be 'A Big Catalyst For Bitcoin,' BlackRock's Head Of Digital Assets Says
Robbie Mitchnick, suggests potential U.S. recession could drive Bitcoin's next bull cycle due to expected liquidity injections. Mitchnick argues Bitcoin's scarcity, decentralization, and independence position it as long-term hedge during economic stress.
Breast Cancer Therapeutics Market Size to Reach US$ 63.9 Billion by 2030, Driven by Innovations and Growing Demand, Says The Insight Partners
US & Canada, March 19, 2025 ( GLOBE NEWSWIRE ) -- According to a comprehensive report from The Insight Partners,"Breast Cancer Therapeutics Market Size and Forecasts ( 2020 - 2030 ) , Global and Regional Share, Trends, and Growth Opportunity Analysis Report", The global breast cancer ...

